Current Report Filing (8-k)
March 22 2023 - 10:10AM
Edgar (US Regulatory)
0001622879
false
0001622879
2023-03-13
2023-03-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
Date of Report (Date of earliest event
reported): March 22, 2023 (March 13,
2023)
Medicine Man
Technologies, Inc.
(Exact Name of Registrant as
Specified in Its Charter)
Nevada |
000-55450 |
46-5289499 |
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
4880 Havana Street, Suite 201
Denver, Colorado |
|
80239 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
|
|
|
(303) 371-0387 |
(Registrant’s Telephone Number, Including Area Code) |
|
|
|
Not Applicable |
(Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
Title of Each Class |
|
Trading Symbol(s) |
|
Name of Each Exchange On Which
Registered |
Not applicable |
|
Not applicable |
|
Not applicable |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
Item 8.01 Other Events.
On March 13, 2023, the
Board of Directors of Medicine Man Technologies, Inc. (the “Company”) determined that the date of its 2023 Annual Meeting
of Stockholders (the “2023 Annual Meeting”) will be Thursday, June 22, 2023. The time, location, and other meeting details
for the 2023 Annual Meeting will be set forth in the Company’s proxy statement for the 2023 Annual Meeting, which will be filed
prior to the 2023 Annual Meeting with the Securities and Exchange Commission (“SEC”).
The record date for the
determination of stockholders entitled to receive notice of and to vote at the 2023 Annual Meeting will be April 24, 2023.
Due to the fact that
the meeting date for the 2023 Annual Meeting has changed by more than 30 days prior to the anniversary of the Company’s stockholder
meeting in 2022, the Company is providing the due date for submissions of any qualified stockholder proposals pursuant to Rule 14a-8 under
the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and for any stockholder nomination or proposal outside
of Rule 14a-8. The deadlines for any stockholder proposals pursuant to Rule 14a-8 under the Exchange Act, and for any stockholder nomination
or proposal outside of Rule 14a-8, as listed in the Company’s Proxy Statement on Schedule 14A, as filed with the SEC on November
1, 2022, are no longer applicable.
For stockholders who wish to present a proposal to be considered for
inclusion in the Company’s proxy materials for the Annual Meeting, the Company has set a deadline for the receipt of such proposals
in accordance with Rule 14a-8 under the Exchange Act. To be considered timely, a stockholder must submit its proposal in writing by April
17, 2023 at the address set forth below. The Company has determined April 17, 2023, to be a reasonable time before it begins to print
and send the proxy materials. Stockholder proposals referred to in this paragraph must also comply with all applicable requirements of
Rule 14a-8.
Pursuant to the Company’s bylaws, in order to be
considered timely, stockholder proposals and nominations submitted outside of Rule 14a-8 of the Exchange Act must be submitted in writing
at the address below, no earlier than close of business on March 24, 2023, and no later than close of business on May 23, 2023. In addition to satisfying the requirements under the Company’s bylaws,
to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than the Company’s
nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than April 24, 2023.
Written notice for any such proposals, nominations or other business
must be received by the Company at its principal executive office (Medicine Man Technologies, Inc., Attention: General Counsel, 4880 Havana
Street, Suite 201, Denver, Colorado 80239) by the applicable deadline and must comply with the procedures and requirements of applicable
SEC rules and the Company’s bylaws.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
MEDICINE MAN TECHNOLOGIES, INC. |
|
|
|
By: |
/s/ Daniel R. Pabon |
Date: March 22, 2023 |
|
Daniel R. Pabon |
|
|
General Counsel |
Medicine Man Technologies (CE) (USOTC:SHWZ)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medicine Man Technologies (CE) (USOTC:SHWZ)
Historical Stock Chart
From Jul 2023 to Jul 2024